Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis

Arthritis and Rheumatism

Volumn 65, Issue 1, 2013, Pages 226-235

  Liu, Xiaochun ^a   Mayes, Maureen D ^a   Tan, Filemon K ^a   Wu, Minghua ^a   Reveille, John D ^a   Harper, Brock E ^b   Draeger, Hilda T ^c   Gonzalez, Emilio B ^b   Assassi, Shervin ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; CHEMOATTRACTANT; CHEMOKINE; CREATINE KINASE; DNA DIRECTED RNA POLYMERASE III; GAMMA INTERFERON;

ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; ETHNICITY; FEMALE; FORCED VITAL CAPACITY; GAS DIFFUSION; GENE EXPRESSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MUSCLE; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; SEROLOGY; SKIN; STRATIFICATION; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHEMOKINES; CHILD; FEMALE; HUMANS; INTERFERONS; MALE; MIDDLE AGED; PROGNOSIS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TRANSCRIPTOME; YOUNG ADULT;

EID: 84871784398     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37742     Document Type: Article

References (30)

1. York MR, Nagai T, Mangini AJ, Lemaire R, van Seventer JM, Lafyatis R,. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and Toll-like receptor agonists. Arthritis Rheum 2007; 56: 1010-20.
2. Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C, et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 2006; 45: 694-702.
3. Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011; 70: 2029-36.
4. Duan H, Fleming J, Pritchard DK, Amon LM, Xue J, Arnett HA, et al. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum 2008; 58: 1465-74.
5. Bos CL, van Baarsen LG, Timmer TC, Overbeek MJ, Basoski NM, Rustenburg F, et al. Molecular subtypes of systemic sclerosis in association with anti-centromere antibodies and digital ulcers. Genes Immun 2009; 10: 210-8.
6. Assassi S, Mayes MD, Arnett FC, Gourh P, Agarwal SK, McNearney TA, et al. Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum 2010; 62: 589-98.
7. Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006; 3: e491.
8. Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009; 60: 3098-107.
9. Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009; 60: 3436-46.
10. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
11. Gourh P, Arnett FC, Assassi S, Tan FK, Huang M, Diekman L, et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 2009; 11: R147.
12. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003; 100: 2610-5.
13. Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999; 26: 2159-67.
14. Bombardieri S, Medsger TA Jr, Silman AJ, Valentini G,. The assessment of the patient with systemic sclerosis: introduction. Clin Exp Rheumatol 2003; 21: S2-4.
15. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-5.
16. Furst D, Khanna D, Matucci-Cerinic M, Clements P, Steen V, Pope J, et al. Systemic sclerosis-continuing progress in developing clinical measures of response. J Rheumatol 2007; 34: 1194-200.
17. Steele R, Hudson M, Lo E, Baron M, on behalf of the Canadian Scleroderma Research Group. Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res (Hoboken) 2012; 64: 519-24.
18. Farina G, Lafyatis D, Lemaire R, Lafyatis R,. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2010; 62: 580-8.
19. Eloranta ML, Franck-Larsson K, Lovgren T, Kalamajski S, Ronnblom A, Rubin K, et al. Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 2010; 69: 1396-402.
20. Steen VD,. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005; 35: 35-42.
21. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-15.
22. Steen VD, Medsger TA,. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-4.
23. Solans R, Bosch JA, Esteban I, Vilardell M,. Systemic sclerosis developing in association with the use of interferon α therapy for chronic viral hepatitis. Clin Exp Rheumatol 2004; 22: 625-8.
24. Beretta L, Caronni M, Vanoli M, Scorza R,. Systemic sclerosis after interferon-α therapy for myeloproliferative disorders. Br J Dermatol 2002; 147: 385-6.
25. Black CM, Silman AJ, Herrick AI, Denton CP, Wilson H, Newman J, et al. Interferon-α does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999; 42: 299-305.
26. Rabquer BJ, Tsou PS, Hou Y, Thirunavukkarasu E, Haines GK III, Impens AJ, et al. Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis. Arthritis Res Ther 2011; 13: R18.
27. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Giuggioli D, Colaci M, et al. CXCL10 (α) and CCL2 (β) chemokines in systemic sclerosis-a longitudinal study. Rheumatology (Oxford) 2008; 47: 45-9.
28. Waddell SJ, Popper SJ, Rubins KH, Griffiths MJ, Brown PO, Levin M, et al. Dissecting interferon-induced transcriptional programs in human peripheral blood cells. PLoS One 2010; 5: e9753.
29. Weckerle CE, Mangale D, Franek BS, Kelly JA, Kumabe M, James JA, et al. Large scale analysis of tumor necrosis factor α levels in systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2947-52.
30. Greenblatt MB, Sargent JL, Farina G, Tsang K, Lafyatis R, Glimcher LH, et al. Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets. Am J Pathol 2012; 180: 1080-94.